A promising but controversial new approach to treating blood cancer could be in trouble in the earliest innings of human testing after Celgene pulled the plug on a trailblazing clinical trial.
On Monday, Celgene (CELG) terminated a Phase 1 study of CC-90002, which targets a protein that helps cancer cells stay out of the immune system’s crosshairs. In an update to ClinicalTrials.gov, Celgene said it canceled the CC-90002 study because early results “did not offer a sufficiently encouraging profile” to move forward.
What’s the reason for Celgene going down even after beating the estimates and lifting 2018 outlook? https://news.alphastreet.com/celgene-celg-stock-q3-2018-earnings/
Based on some preclinical data this wasn’t surprising http://clincancerres.aacrjournals.org/content/23/4/1068.long
Comments are closed.